Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer

The purpose of this research is to observe the effects of using a new combination of drugs to inhibit tumor growth.

Trial Details

NCT ID
NCT07829185
Phase
PHASE1
Sponsor
University of Oklahoma
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • modified FOLFIRINOX
  • Pentamidine 300 MG Injection
Locations (sample)
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Written informed consent signed and dated by the patient
  • At least 18 years-of-age at the time of signature of the informed consent form (ICF)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Patients with a confirmed diagnosis of locally advanced, unresectable and/or metastatic pancreatic cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →